{"id":"W2749747068","doi":"10.1016/s1470-2045(17)30517-x","title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1113,"is_retracted":false,"has_abstract":false,"ca_institutions":"Health Sciences Centre; Foothills Medical Centre; University of Calgary; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"Celldex Therapeutics","keywords":"Temozolomide; Medicine; Internal medicine; Clinical endpoint; Oncology; Progression-free survival; Phases of clinical research; Clinical trial; Chemotherapy; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05302134748243224,"score_gpt":0.3716507209685209,"score_spread":0.3186293734860886,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}